ATE542570T1 - Verwendung kardiotonischer steroiden als na/k- atpase liganden zur hautbehandlung - Google Patents

Verwendung kardiotonischer steroiden als na/k- atpase liganden zur hautbehandlung

Info

Publication number
ATE542570T1
ATE542570T1 AT07762999T AT07762999T ATE542570T1 AT E542570 T1 ATE542570 T1 AT E542570T1 AT 07762999 T AT07762999 T AT 07762999T AT 07762999 T AT07762999 T AT 07762999T AT E542570 T1 ATE542570 T1 AT E542570T1
Authority
AT
Austria
Prior art keywords
skin treatment
cardiotonic steroids
atpase
ligands
atpase ligands
Prior art date
Application number
AT07762999T
Other languages
English (en)
Inventor
Zijian Xie
Joseph Shapiro
Original Assignee
Univ Toledo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Toledo filed Critical Univ Toledo
Application granted granted Critical
Publication of ATE542570T1 publication Critical patent/ATE542570T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63—Steroids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
    • A61K2800/782—Enzyme inhibitors; Enzyme antagonists
AT07762999T 2006-01-31 2007-01-30 Verwendung kardiotonischer steroiden als na/k- atpase liganden zur hautbehandlung ATE542570T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US76378306P 2006-01-31 2006-01-31
PCT/US2007/002365 WO2007089688A2 (en) 2006-01-31 2007-01-30 Na/k-atpase ligand

Publications (1)

Publication Number Publication Date
ATE542570T1 true ATE542570T1 (de) 2012-02-15

Family

ID=38327955

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07762999T ATE542570T1 (de) 2006-01-31 2007-01-30 Verwendung kardiotonischer steroiden als na/k- atpase liganden zur hautbehandlung

Country Status (7)

Country Link
US (3) US8906891B2 (de)
EP (1) EP1993672B1 (de)
JP (1) JP5484735B2 (de)
CN (1) CN101374571B (de)
AT (1) ATE542570T1 (de)
CA (1) CA2641303C (de)
WO (1) WO2007089688A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007089688A2 (en) 2006-01-31 2007-08-09 The University Of Toledo Na/k-atpase ligand
CN101541319B (zh) 2006-10-31 2013-09-18 托莱多大学 Src和Src家族激酶的Na+/K+-ATP酶特异性肽抑制剂/激活剂
CA2774486C (en) * 2009-09-16 2019-06-04 The University Of Toledo Hydroxy xanthone-based na/k atpase ligands useful in treating cardiac hypertrophy, and congestive heart failure
US8835171B2 (en) 2010-01-13 2014-09-16 The University Of Toledo Materials and methods related to sodium/potassium adenosine triphosphase and cholesterol
FI3805243T3 (fi) * 2019-10-09 2024-02-07 Windtree Therapeutics Inc Androstaanijohdannaisia, joilla on aktiivisuus puhtaina tai pääasiallisesti puhtaina SERCA2a:n stimulaattoreina, sydämen vajaatoiminnan hoitoon

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2698822A (en) * 1951-04-28 1955-01-04 Fougera & Co Inc E Cardiac glycoside buccal composition
US3122475A (en) * 1960-02-25 1964-02-25 Schaeppi Ag Dr Circulatory adjuvant shell elements for cardiac glycoside suppository cores
US3687944A (en) * 1970-05-08 1972-08-29 George R Pettit Process for the preparation of bufalin and related compounds
SE426548B (sv) * 1978-12-05 1983-01-31 Haessle Ab Fast farmaceutisk beredning innehallande en terapeutiskt effektiv hjertglykosid och en polymer
US5153178A (en) * 1982-05-14 1992-10-06 Maroko Peter R Compositions and method of treatment for improving circulatory performance
DE69625804T2 (de) * 1995-02-21 2003-07-31 Unigen Pharmaceuticals Inc Aus aloe barbadensis isoliertes cinnamoyl-c-glykosid chromon
US5977077A (en) 1995-08-28 1999-11-02 Interlab Corporation Xanthone analogs for the treatment of infectious diseases
US5891855A (en) * 1996-02-12 1999-04-06 The Scripps Research Institute Inhibitors of leaderless protein export
US6531165B2 (en) * 1997-01-17 2003-03-11 Shiseido Company, Ltd. Collagen production promoter composition
US5989591A (en) 1997-03-14 1999-11-23 American Home Products Corporation Rapamycin formulations for oral administration
US20040186071A1 (en) * 1998-04-13 2004-09-23 Bennett C. Frank Antisense modulation of CD40 expression
KR100342440B1 (ko) * 1999-12-24 2002-07-04 손 경 식 섬수 정제엑스를 이용한 성신경과민증 예방 및 치료용 의약조성물 및 그 제조방법
US20030180379A1 (en) * 2000-07-27 2003-09-25 Burrell Robert E. Solutions and aerosols of metal-containing compounds
WO2002014343A1 (en) * 2000-08-17 2002-02-21 Terness, Peter Bufadienolide derivatives and use as immunosuppressive, antiinflammatory and analgesic agents
WO2002092573A2 (en) 2001-05-16 2002-11-21 Vertex Pharmaceuticals Incorporated Heterocyclic substituted pyrazoles as inhibitors of src and other protein kinases
US20060128699A1 (en) 2002-11-07 2006-06-15 Welsh William J Novel pharmacophore for the discovery and testing of na,k-atpase inhibitor compositions and methods for their use in treating cardiovascular diseases and conditions
US20050026849A1 (en) * 2003-03-28 2005-02-03 Singh Chandra U. Water soluble formulations of digitalis glycosides for treating cell-proliferative and other diseases
EP1734975B1 (de) * 2004-03-19 2015-06-10 Herbs Spring, LLC Pflanzliche therapie zur behandlung von nahrungsmittelallergien
FR2871060B1 (fr) * 2004-06-08 2008-07-11 Ajinomoto Kk Agent suppresseur pour l'inflammation et procede l'utilisant
US20060004002A1 (en) * 2004-07-02 2006-01-05 Thomas Thrash Small molecule thienopyrimidine-based protein tyrosine kinase inhibitors
US20060135468A1 (en) 2004-09-02 2006-06-22 Bionaut Pharmaceuticals, Inc. Treatment of refractory cancers using NA+/K+ ATPase inhibitors
US20060205679A1 (en) * 2004-10-22 2006-09-14 Azaya Therapeutics, Inc. Topical and oral formulations of cardiac glycosides for treating skin diseases
US7402325B2 (en) * 2005-07-28 2008-07-22 Phoenix Biotechnology, Inc. Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
US20070092970A1 (en) * 2005-10-25 2007-04-26 Liang Dong C High-throughput screening assay for Na, K-ATPase using atomic absorption spectroscopy
WO2007089688A2 (en) 2006-01-31 2007-08-09 The University Of Toledo Na/k-atpase ligand
EP2032143A1 (de) 2006-05-09 2009-03-11 University Of Louisville Research Foundation, Inc. Behandlung von krebs mit herzglykosiden
US7858126B2 (en) * 2006-08-31 2010-12-28 Trinity Laboratories Inc. Derivatives of sandalwood oil and santalols for treating cold sores and herpes
CN101541319B (zh) 2006-10-31 2013-09-18 托莱多大学 Src和Src家族激酶的Na+/K+-ATP酶特异性肽抑制剂/激活剂
CA2739029C (en) * 2008-10-14 2018-07-10 Nerium Biotechnology, Inc. Process for extracting cardiac glycosides from plants and compositions comprising cardiac glycosides from nerium oleander
EP2361097A4 (de) 2008-12-12 2012-04-25 Univ Toledo Scr-hemmer mit aus na/k-atpase abgeleiteten peptiden sowie ouabain-antagonisten und anwendungen davon
CA2774486C (en) * 2009-09-16 2019-06-04 The University Of Toledo Hydroxy xanthone-based na/k atpase ligands useful in treating cardiac hypertrophy, and congestive heart failure
US8835171B2 (en) * 2010-01-13 2014-09-16 The University Of Toledo Materials and methods related to sodium/potassium adenosine triphosphase and cholesterol

Also Published As

Publication number Publication date
EP1993672A2 (de) 2008-11-26
CN101374571A (zh) 2009-02-25
CA2641303C (en) 2013-05-14
US9492463B2 (en) 2016-11-15
US9072751B2 (en) 2015-07-07
US20140128356A1 (en) 2014-05-08
US8906891B2 (en) 2014-12-09
WO2007089688A2 (en) 2007-08-09
WO2007089688A3 (en) 2008-03-06
JP5484735B2 (ja) 2014-05-07
US20150342966A1 (en) 2015-12-03
CA2641303A1 (en) 2007-08-09
CN101374571B (zh) 2013-07-17
EP1993672A4 (de) 2009-09-16
JP2009525334A (ja) 2009-07-09
US20090226513A1 (en) 2009-09-10
EP1993672B1 (de) 2012-01-25

Similar Documents

Publication Publication Date Title
PH12018500045A1 (en) Compositions and methods for treating and diagnosing asthma
MY159815A (en) Notch1 receptor binding agents and methods of use thereof
GB2467467C (en) TAZ/WWTR1 for diagnosis and treatment of cancer
MX2009012722A (es) Variantes geneticas sobre chr 5p12 y 10q26 como marcadores para el uso en la evaluacion del riesgo, diagnostico, pronostico y tratamiento del cancer de mama.
WO2010059969A3 (en) Use of anti-vegf antibody in combination with chemtherapy for treating breast cancer
WO2010085542A3 (en) Biomarkers related to age-related macular degeneration (amd)
WO2013182912A3 (en) Method for the diagnosis, prognosis and treatment of lung cancer metastasis
AU2008298744A8 (en) MiRNA expression in human peripheral blood microvesicles and uses thereof
EA201590630A1 (ru) Способы лечения и диагностики, связанные с лизилоксидазоподобным белком 2 (loxl2)
EP3683320A3 (de) Mirna-fingerabdruck in der diagnose von lungenkrebs
CY1111714T1 (el) Δεσμευτικες πρωτεϊνες αυξητικου παραγοντα ηπατοκυτταρων (hgf).
WO2014057357A3 (en) Method for the diagnosis, prognosis and treatment of prostate cancer metastasis using c-maf
MX2013003880A (es) Metodo para diagnostico, pronostico y tratamiento de la metastasis de carcer de mama.
WO2009015050A3 (en) Gene expression profile for predicting ovarian cancer patient survival
WO2008073177A3 (en) Expression profiles associated with irinotecan treatment
ATE542570T1 (de) Verwendung kardiotonischer steroiden als na/k- atpase liganden zur hautbehandlung
MX338694B (es) Composiciones y metodos para el diagnostico y el tratamiento de tumores.
WO2011134670A3 (en) Diagnostic method for predicting the response of a patient to chemovirotherapy or radiovirotherapy
WO2011106785A3 (en) Methods of identifying agents effective to treat cognitive decline and diseases associated therewith
WO2013106766A3 (en) THERAPEUTIC INDICATIONS OF miR-1291
ATE487947T1 (de) Verfahren zur diagnose und behandlung auf nr2- peptiden beruhender zerebrovaskulärer ereignisse
WO2009091230A3 (ko) 유방암 모니터링,진단 및 스크리닝용 단백질 마커 및 이를 이용한 유방암 모니터링,진단 및 스크리닝 방법
EA201490201A1 (ru) Выявление экспрессии гена prame при раковом заболевании
TR201910508T4 (tr) Prostat kanserinin tedavisi ve prostat kanseri hastalarına yönelik prognozun belirlenmesine yönelik bir yöntem.
WO2010026473A3 (en) Pta072 protein